Update on Glaxo/Theravance's COPD Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:33PM CDT
Glaxo (GSK) and partner Theravance (THRX) announced the initiation of a phase III study on Relvar Ellipta.
Inside Valeant Pharmaceuticals' Bid for Allergan
Brendan Mathews, The Motley Fool - Motley Fool - Thu Apr 24, 5:30PM CDT
Earlier this week, Valeant Pharmaceutical made a public offer to buy rival Allergan . Let's review the major questions this huge potential deal raises, to see whether it's a smart move – and whether or not it'll actually happen. What is...
Valeant Eyes Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:40PM CDT
Shares of Allergan (AGN) gained 15.2% after Valeant Pharmaceuticals International, Inc. (VRX) and Pershing Square Capital Management, L.P made a formal proposal to acquire the former.
Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available
CNW Group - Thu Apr 24, 2:16PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management L.P. ("Pershing Square"
Eli Lilly Q1 Earnings In-Line, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:50PM CDT
Eli Lilly's (LLY) first quarter revenues were hurt by the genericization of two major products - Cymbalta and Evista.
Zimmer Bolts on Biomet for $13.4B
at The Street - Thu Apr 24, 10:47AM CDT
Sponsors Blackstone, TPG, KKR and Goldman forgo planned IPO in sale of orthopedic device maker.
Botox at the Center of Recent Healthcare M&A Flurry
at The Street - Thu Apr 24, 10:07AM CDT
How wrinkle reduction is at the crux of the recent M&A frenzy....
Jim Cramer's 'Mad Money' Recap: The Market's New Reality
at The Street - Wed Apr 23, 7:20PM CDT
Investors are focusing on the positive instead of the negative, Cramer says.
Encouraging Results from Pfizer's Xeljanz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 5:20PM CDT
Pfizer Inc. (PFE) announced encouraging top-line results from two pivotal phase III studies from the OPT Program on Xeljanz.
Fitch Places Allergan's Ratings on Negative Watch
Business Wire - Wed Apr 23, 2:32PM CDT
Fitch Ratings has placed the ratings for Allergan Inc. (Allergan), including the 'A+' Issuer Default Rating (IDR), on Rating Watch Negative. The rating action stems from Valeant Pharmaceuticals International Inc.'s (Valeant) unsolicited offer to acquire Allergan for approximately $45.6 billion. The rating action applies to $2.1 billion of outstanding Allergan debt. A complete list of ratings is provided at the end of this release.
Can Allergan Find an Alternative To Valeant?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 23, 1:30PM CDT
No one will accuse Valeant CEO Mike Pearson of lacking boldness. He has laid out a strategy for turning Valeant into one of the largest pharmaceutical/med-tech companies in the world and has proven more than willing to turn to bold...
Stock Market News for April 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 9:06AM CDT
Benchmarks ended higher on Tuesday boosted by better-than-expected corporate results
Critical Alerts For Allergan, SunEdison, Valeant Pharmaceuticals, Shire PLC, and Paychex Released By InvestorsObserver
PR Newswire - Wed Apr 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AGN, SUNE, VRX, SHPG, and PAYX.
Stock Price Movements, Collaborations, Earnings Releases, Upcoming Earnings and Conference Call Schedules, and Legal Updates - Analyst Notes on Allergan, Aetna, Abbott, Amgen and Medtronic
PR Newswire - Wed Apr 23, 8:30AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Aetna Inc. (NYSE: AET), Abbott Laboratories (NYSE: ABT), Amgen Inc. (NASDAQ: AMGN) and Medtronic Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1477-100free.
Allergan, Inc.: Another Billion-Dollar Buyout Target
Max Macaluso and Michael Douglass, The Motley Fool - Motley Fool - Wed Apr 23, 8:15AM CDT
Earlier this week, investors following the pharmaceutical industry may have been surprised to hear that Pfizer was interested in acquiring AstraZeneca . However, the billion-dollar buyout news didn't stop there. Yesterday, shares of Allergan ,...
Why Valeant International Inc. Is Acquiring Botox and Juvederm Maker Allergan
Beth Nichols, The Motley Fool - Motley Fool - Wed Apr 23, 7:50AM CDT
Valeant Pharmaceuticals announced yesterday that it plans to acquire Allergan with the help of investor Bill Ackerman. Should the plan succeed, the acquisition would create a dermatology and ophthalmology giant and bring a number of the leading...
Allergan Inc. (AGN) in Focus: Stock Rallies 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:44AM CDT
Allergan Inc. was a big mover last session, as the company saw its shares surge over 15.0% on the day.
How Will Allergan (AGN) Stock Be Affected By Poison Pill Stance Against Valeant (VRX), Ackman?
at The Street - Wed Apr 23, 7:22AM CDT
Shares of Allergan (AGN) are slightly higher in pre-market trade after the health care company adopted a poison pill defense against the unsolicited $46 billion bid takeover from Valeant Pharmaceuticals (VRX) and activist investor Bill Ackman.
Downgrade Alert for Allergan (AGN)
Comtex SmarTrend(R) - Wed Apr 23, 6:57AM CDT
Allergan (AMEX:AGN) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $163.65 on volume of 32.4 million shares, above average daily volume of 3.4 million. In the past 52 weeks, shares of Allergan have traded between a low of $81.33 and a high of $165.45 and closed yesterday at $163.65, which is 101% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.7% while the 50-day MA has advanced 1.1%.